Brought to you by 
Specialised Therapeutics gets exclusive Asian rights to Puma's Nerlynx
27 Nov 2017
Executive Summary
Puma Biotechnology Inc. granted Specialised Therapeutics Asia Pte. Ltd. exclusive rights to sell the breast cancer therapy Nerlynx (neratinib) in Southeast Asia, including Australia, Singapore, Malaysia, Brunei, and New Zealand.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Specialised Therapeutics gets exclusive Asian rights to Puma's Nerlynx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice